公开(公告)号：US20220112276A1

公开(公告)日：2022-04-14

申请号：US17498418

申请日：2021-10-11

Applicant: JANSSEN BIOTECH, INC.

Inventor： Paul B. HARVILLA ,  Martin Jack BORROK, III ,  Ninkka TAMOT

IPC: C07K16/18 ,  A61K9/00 ,  A61P29/00 ,  A61P3/10 ,  A61P31/00 ,  A61P1/00 ,  A61P35/00

Abstract: Single domain antibodies that bind to pIgR are described. The single domain antibodies may compete with IgA binding to pIgR, or alternatively, the single domain antibodies may compete with IgA binding to pIgR. The single domain antibodies may be coupled to therapeutic agents so as to facilitate delivery of the therapeutic agent to the mucosal layer via pIgR-mediated transcytosis. The therapeutic agent can be, e.g., a small molecule or large molecule such as an antibody.

公开(公告)号：US20220305056A1

公开(公告)日：2022-09-29

申请号：US17637946

申请日：2020-08-26

Applicant: JANSSEN BIOTECH, INC.

Inventor： Rajkumar GANESAN ,  Bharathikumar Vellalore MARUTHACHALAM ,  Sathyadevi VENKATARAMANI ,  Iqbal GREWAL ,  Sanjaya SINGH ,  Paul HARVILLA ,  Martin Jack BORROK III ,  Ninkka TAMOT ,  Yonghai LI

IPC: A61K35/17 ,  C07K16/44 ,  C07K16/30 ,  C07K16/28 ,  C07K14/725 ,  A61P35/00

Abstract: Provided herein are chimeric antigen receptors (CARs), cells comprising the CARs, monoclonal and bispecific antibodies or antigen-binding fragments thereof, and kits comprising the same. The CARs and bispecific antibodies are designed to target at least one tumor antigen and at least one tumor in methods of treating cancer in subjects in need thereof.

公开(公告)号：US20240166720A1

公开(公告)日：2024-05-23

申请号：US18549795

申请日：2022-03-11

Applicant: Janssen Biotech, Inc.

Inventor： Ninkka TAMOT ,  Paul B. HARVILLA ,  Douglas YAMADA ,  Manuel Alejandro SEPULVEDA ,  Rajkumar GANESAN ,  Sanjaya SINGH

IPC: C07K14/705 ,  A61K39/00 ,  A61K39/39 ,  A61P37/04

CPC classification number: C07K14/70575 ,  A61K39/39 ,  A61P37/04 ,  A61K2039/55516 ,  C07K2319/00 ,  C07K2319/30

Abstract: Provided herein are bioengineered immunomodulatory fusion proteins and uses thereof for modulating immune responses, as well as uses for improving a response of a subject to a vaccine, or uses for treating a disease or disorder, such as cancer or a pathogen infection. Provided herein is a single chain trimeric CD40L Fc fusion protein comprising (a) three CD40 ligand CD40L subunits covalently linked to one another by peptide linkers (CD40L trimer); and (b) an Fc monomer peptide.

公开(公告)号：US20220033522A1

公开(公告)日：2022-02-03

申请号：US17391744

申请日：2021-08-02

Applicant: JANSSEN BIOTECH, INC.

Inventor： Rajkumar GANESAN ,  Adam ZWOLAK ,  Ian WHITE ,  Ninkka TAMOT ,  Paul B. HARVILLA ,  Rajitha DODDAREDDY ,  Sanjaya SINGH ,  Martin Jack BORROK III

IPC: C07K16/40 ,  C07K16/28 ,  C07K16/10

Abstract: Provided herein are multispecific molecules comprising a first binding domain that specifically binds to polymeric immunoglobulin receptor (pIgR) and a second binding domain that specifically binds to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and related methods for the treatment of patients infected with SARS-CoV-2.